Journal article
Prostate Specific Antigen Screening on a Nationwide Level: Featuring the Contribution of Race and Life Expectancy in Decision Making
Clinical genitourinary cancer, Vol.22(2), pp.269-280.e2
04/01/2024
DOI: 10.1016/j.clgc.2023.11.009
PMID: 38233279
Abstract
There is limited evidence regarding frequency/determinants of PSA screening in African American men with extended life expectancy. This is the first study analyzing nationwide trends in PSA screening, over a nearly 20-year period, with a special focus on African American's life expectancy. While PSA screening increased for those with extended life expectancy, life expectancy was not an independent predictor of PSA screening on multivariable analysis. Background: Estimation of life expectancy (LE) is important for the relative benefit of prostate specific antigen (PSA) screening. Limited data exists regarding screening for Black men with extended LE. The aim of the current study was to assess temporal trends in screening in United States (US) Black men with limited vs. extended LE, using a nationally representative dataset. Materials and Methods: Using the National Health Institution Survey (NHIS) 2000 to 2018, men aged >40 without prior history of prostate cancer (PCa) who underwent PSA screening in the last 12 months were stratified into limited LE (ie, LE < 15 years) and extended LE (ie, LE >15 years) using the validated Schonberg index. LE-stratified temporal trends in PSA screening were analyzed for all men, and then in Black men. Weighted multivariable analyses and dominance analyses identified the predictors of PSA screening. Results: PSA screening declined over the study period both for all eligible men with limited and extended LE, particularly between NHIS 2008 and 2013 (27.9%20.7% in the extended). Screening increased significantly in Black men with extended LE (17.6% in 2010-25.7% in 2018). However, LE was not an independent predictor of screening in the Black cohort. Prior recipient of colonoscopy (55%57%) and visit to health care provider (24%-32%) were the most important determinants for screening. Conclusion: For US men with extended LE, only 1 in 4 receive PSA screening, with a decline over the study-period. Screening rates increased for Black men. However, these changes were not driven by LE consideration itself, but participation in other screenings and access to a provider.
Details
- Title: Subtitle
- Prostate Specific Antigen Screening on a Nationwide Level: Featuring the Contribution of Race and Life Expectancy in Decision Making
- Creators
- Deepansh Dalela - University Medical Center of El PasoNicholas J. Corsi - The University of Texas Southwestern Medical CenterChandler Bronkema - Harvard UniversityAkshay Sood - Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USASohrab Arora - Henry Ford HospitalSami E. Majdalany - Henry Ford HospitalMohit Butaney - Henry Ford HospitalMarcus Jamil - Henry Ford HospitalPin Li - Henry Ford Health SystemIsaac Palma-Zamora - Henry Ford HospitalNikola Rakic - Baylor College of MedicineNatalija Kovacevic - Henry Ford HospitalWooju Jeong - Henry Ford HospitalMani Menon - Icahn School of Medicine at Mount SinaiCraig G. Rogers - Henry Ford HospitalMara A. Schonberg - Beth Israel Deaconess Medical CenterFiras Abdollah - Henry Ford Hospital
- Resource Type
- Journal article
- Publication Details
- Clinical genitourinary cancer, Vol.22(2), pp.269-280.e2
- DOI
- 10.1016/j.clgc.2023.11.009
- PMID
- 38233279
- NLM abbreviation
- Clin Genitourin Cancer
- ISSN
- 1558-7673
- eISSN
- 1938-0682
- Publisher
- Cig Media Group, Lp
- Number of pages
- 14
- Language
- English
- Date published
- 04/01/2024
- Academic Unit
- Urology
- Record Identifier
- 9984949455402771
Metrics
3 Record Views